Public Summary Sample Clauses

Public Summary. This document is the Innovation Plan for the Centre of Excellence (XxX) for Computational Biomedicine (CompBioMed), applicable to Phase 2 of the XxX (CompBioMed 2) and building on the innovation infrastructure established during the first 3 years of operation of the XxX in Phase 1 (CompBioMed 1). The plan outlines how all services, software and know-how developed during the project can be assessed for their innovation potential. It provides guidance to support individual researchers in making that assessment and undertaking any planning of specific exploitation routes. The innovation management activities during CompBioMed 1 have resulted in a substantial funded programme of development across our core work packages, taking our software and services to full usability by the biomedical community. These work packages will also determine the role our XxX will play in supporting that community in their use in the future. This plan is complementary to the core funded activities and will maintain the internal infrastructure to support the addition of new results to the innovation process.
Sample 1Sample 2
AutoNDA by SimpleDocs
Public Summary. The Commissioner shall make available to the public a summary of the report required by sub- section (a) that includes, at a minimum— (1) a description of the type of merchandise with respect to which investigations were ini- tiated under subsection (b) of section 1517 of this title; (2) the amount of additional duties deter- mined to be owed as a result of such investiga- tions and the amount of such duties that were collected; (3) an identification of the countries of ori- gin of covered merchandise determined under subsection (c) of such section 1517 of this title to be entered into the customs territory of the United States through evasion; and
Sample 1Sample 2
Public Summary. Work Package 2 (WP2) in the CompBioMed2 project aggregates the computational biomedical research activities of the project. The leader of this work package is the University of Amsterdam (UvA). Computational Biomedicine is highly diverse, subsuming a large range of modelling and simulation methods, each applicable to a specific level of human body organisation. State of the art mathematical models in Computational Biomedicine need to take into account the inherent multiphysics and multiscale character of human physiology. This means that, typically, different types of models, representing different scales within a given (patient specific) biomedical system, often need to be taken into account, including the details as to how to correctly connect these different models. The main objective of this work package is to lay the groundwork for the application of High Performance Computer (HPC)-based Computational Biomedicine approaches to a great number of therapeutic areas. The HPC requirements of our users are as diverse as the communities we represent; therefore, we must support a wide palette of codes potentially scaling to the exascale. These codes can be categorised based on their execution pattern as (I) monolithic code, (II) coupled code, or (III) complex workflow requiring support for advanced execution patterns on a range of diverse and geographically distributed platforms. This document reports on the scientific progress achieved within our application portfolio and includes a list and description of the publicly available user resources that aim to enable efficient external code adoption and that will collectively form the “best practices” guide for external users.
Sample 1Sample 2
Public Summary. The Project Handbook (PH) for CompBioMed2 is a document describing the project organisation and internal procedures. In a project of this size it is vital that all partners communicate effectively but without adding undue pressure to their business as usual. The CompBioMed2 project handbook details the procedure for documentation management, communication mechanisms and deliverable submission control. Its main goal is to allow easy access to communication methods and to the management structure by acting as a reference document for all the partners to ensure that project outcomes are uniform and accessible.
Sample 1
Public Summary. CompBioMed is a user-driven Centre of Excellence which serves users from academia, industry and clinical practice in promoting and enhancing computational methods and simulation tools in the biomedical domain. The Centre of Excellence (XxX) is also working as contact point for our users’ community by acting as network and incubator centre to promote application usage and integration, through specialised trainings and support activities. The impact of the XxX within the Computational Biomedicine user community is critically dependent on the ability of the XxX to translate the work done within the consortium partners into tangible and usable services which can help to bring value to the end users. Since the inception of CompBioMed2, leveraging the simulation community grown out of CompBioMed1, we have built several core services which are maintained and offered to our userbase. These services have been designed to support the needs of the biomedical community in delivering state of the art solutions, access to training material and efficient use of high- performance and high-throughput infrastructures. This deliverable presents an overview of the existing CompBioMed services and we propose a set of guidelines and standards that will help in publishing the service portfolio and to enrich the service offering with more community-driven biomedical solutions. In this work we focus our attention on the currently available services within the project in order to define a service management system, and our plans for its development, to support the delivery of mature compute and data services for the community, which is the real focus of our work in CompBioMed.
Sample 1
Public Summary. Work Package 2 (WP2) in the CompBioMed 2 project aggregates the computational biomedical research activities of the project. The leader of this work package is the University of Amsterdam (UvA). Computational Biomedicine is highly diverse, subsuming a large range of modelling and simulation methods, each applicable to a specific level of human bodily organisation. State of the art mathematical models in Computational Biomedicine need to take into account the inherent multiphysics and multiscale character of human physiology. This means that, typically, different types of models, representing different scales within a given (patient specific) biomedical system, often need to be taken into account, including the details as to how to correctly connect these different models. The main objective of this work package is to lay the groundwork for the application of High Performance Computer (HPC)-based Computational Biomedicine approaches to a great number of therapeutic areas. The HPC requirements of our users are as diverse as the communities we represent; therefore, we must support both monolithic codes, potentially scaling to the exascale, and complex workflows requiring support for advanced execution patterns on a range of diverse and geographically distributed platforms.
Sample 1
Public Summary. CompBioMed is a user-driven Centre of Excellence which serves users from academia, industry, and clinical practice in promoting and enhancing computational methods and simulation tools in the biomedical domain. The Centre of Excellence (XxX) is also working as contact point for our users’ community by acting as network and incubator centre to promote application usage and integration, through specialised training and support activities. The impact of the XxX within the Computational Biomedicine user community is critically dependent on the ability of the XxX to translate the work done within the consortium partners into tangible and usable services which can help to bring value to the end users. Since the inception of CompBioMed2, leveraging the simulation community that has grown out of CompBioMed1, we have built several core services which are maintained and offered to our userbase. These services have been designed to support the needs of the biomedical community in delivering state of the art solutions, access to training material and efficient use of high- performance and high-throughput infrastructures. This deliverable describes the compute and data services developed and delivered within the project. The first part of the document focuses on the applications services available through the project partners, providing an overview of technical characteristics and infrastructure usage. In the second part of the document, we describe the tools and support activities we have been working on in these first 24 months of the project. The goal is to help our partners to deliver mature biomedical solutions and performance improvement, future proofing of biomedical applications, preparing strategies and best practice to exploit current multi-petaflop and emerging exascale resources.
Sample 1
AutoNDA by SimpleDocs
Public Summary. The document reports the process for establishment of the CompBioMed2 Ethics Panel, production of an Ethics Questionnaire, and circulation of the questionnaire to project partners, and summarises the outcomes from this process. The outcomes of the questionnaire were used to produce this Ethics Report at M06 of project activity, which is provided in Section 9 of this document. Section 8.5 describes the process that will be used to ensure ongoing monitoring of the ethical status of CompBioMed2 research activity throughout the project and how this will be used to keep the Ethics Report up to date.
Sample 1

Related to Public Summary

  • Public Reports Promptly after the same become publicly available, copies of all periodic and other reports, proxy statements and other materials filed by any Company with the Securities and Exchange Commission, or any Governmental Authority succeeding to any or all of the functions of said Commission, or with any national securities exchange, or distributed to holders of its Indebtedness pursuant to the terms of the documentation governing such Indebtedness (or any trustee, agent or other representative therefor), as the case may be;

  • Material Non-Public Information Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is in possession of material non-public information.

  • Public/Private Information The Borrower shall cooperate with the Administrative Agent in connection with the publication of certain materials and/or information provided by or on behalf of the Borrower. Documents required to be delivered pursuant to the Loan Documents shall be delivered by or on behalf of the Borrower to the Administrative Agent and the Lenders (collectively, “Information Materials”) pursuant to this Article and the Borrower shall designate Information Materials (a) that are either available to the public or not material with respect to the Borrower and its Subsidiaries or any of their respective securities for purposes of United States federal and state securities laws, as “Public Information” and (b) that are not Public Information as “Private Information”.

  • Public Filings The documents filed by the Company (the "Public Filings") with the Commission at the time they were filed with the Commission, complied in all material respects with the requirements of the 1933 Act, the Securities Exchange Act of 1934, as amended (the "1934 Act"), and the rules and regulations promulgated thereunder, as applicable. The Public Filings do not include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

  • Pricing Information Provided Orally by Underwriters Firm Shares: [—] Price per share: $[—] The Underwriters have an option to purchase up to [—] Option Shares AUSPEX PHARMACEUTICALS, INC. 0000 Xxxxx Xxxxxx Xxxxx Court, Suite 400 La Jolla, CA 92037 X. X. XXXXXX SECURITIES LLC 000 Xxxxxxx Xxxxxx Xxx Xxxx, XX 00000 Ladies and Gentlemen: The undersigned refers to the proposed Underwriting Agreement (the “Underwriting Agreement”) between Auspex Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and the several underwriters named therein (the “Underwriters”), for whom X. X. Xxxxxx Securities LLC (the “Representative”) is acting as representative. As an inducement to the Representative to execute the Underwriting Agreement on behalf of the Underwriters in connection with the proposed public offering of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), pursuant to a Registration Statement on Form S-1, the undersigned hereby agrees that from the date hereof and until 60 days after the public offering date set forth on the final prospectus used to sell the Common Stock (the “Public Offering Date”) pursuant to the Underwriting Agreement (such period being referred to herein as the “Lock-Up Period”), the undersigned will not (and will cause any spouse, domestic partner or immediate family member of the spouse, domestic partner or the undersigned living in the undersigned’s household, any partnership, corporation, limited liability company or other entity within the undersigned’s control, and any trustee of any trust that holds Common Stock or other securities of the Company for the benefit of the undersigned or such spouse, domestic partner or immediate family member not to) offer, sell, contract to sell (including any short sale), pledge, hypothecate, establish an open “put equivalent position” within the meaning of Rule 16a-1(h) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), grant any option, right or warrant for the sale of, purchase any option or contract to sell, sell any option or contract to purchase, or otherwise encumber, dispose of or transfer, or grant any rights with respect to, directly or indirectly, any shares of Common Stock or securities convertible into or exchangeable or exercisable for any shares of Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant), enter into a transaction which would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such aforementioned transaction is to be settled by delivery of the Common Stock or such other securities, in cash or otherwise, or publicly disclose the

  • WHO WILL REVIEW THE INFORMATION DISCLOSED ON THE RELATIONSHIP DISCLOSURE FORM AND ANY UPDATES?

  • Preliminary Offering Memorandum, Time of Sale Information and Offering Memorandum The Preliminary Offering Memorandum, as of its date, did not, the Time of Sale Information, at the Time of Sale, did not, and at the Closing Date, will not, and the Offering Memorandum, in the form first used by the Initial Purchasers to confirm sales of the Securities and as of the Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company and the Guarantors make no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representative expressly for use in the Preliminary Offering Memorandum, the Time of Sale Information or the Offering Memorandum.

  • Root-­‐zone Information Publication ICANN’s publication of root-­‐zone contact information for the TLD will include Registry Operator and its administrative and technical contacts. Any request to modify the contact information for the Registry Operator must be made in the format specified from time to time by ICANN at xxxx://xxx.xxxx.xxx/domains/root/.

  • Pricing Information Each Fund or its designee will furnish Plan Provider on each business day that the New York Stock Exchange is open for business ("Business Day"), with (i) net asset value information as of the close of trading (currently 4:00 p.m. Eastern Time) on the New York Stock Exchange or as at such later times at which a Fund's net asset value is calculated as specified in such Fund's prospectus ("Close of Trading"), (ii) dividend and capital gains information as it becomes available, and (iii) in the case of income Funds, the daily accrual or interest rate factor (mil rate). The Funds shall use their best efforts to provide such information to Plan Provider by 6:00 p.m. Central Time on the same Business Day. Distributor or its affiliate will provide Plan Provider (a) daily confirmations of Account activity within five Business Days after each day on which a purchase or redemption of Shares is effected for the particular Account, (b) if requested by Plan Provider, quarterly statements detailing activity in each Account within fifteen Business Days after the end of each quarter, and (c) such other reports as may be reasonably requested by Plan Provider.

  • Public Use The Recipient will ensure that Infrastructure resulting from any Eligible Project that is not sold, leased, encumbered, or otherwise disposed of, remains primarily for public use or benefit.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!